← Oncology Approval Tracker

FDA DECISION ·

Welireg + Lenvima

belzutifan with lenvatinib · Merck / Eisai

FDA approvalNew or expanded indicationRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with advanced renal cell carcinoma with a clear-cell component following a PD-1 or PD-L1 inhibitor.

LAMPGEN ANALYSIS

Why it matters

The approval gives clinicians a HIF-2α and multikinase inhibitor combination after checkpoint therapy. LITESPARK-011 tested it against cabozantinib.

What research teams should watch

Confirm histology and prior checkpoint exposure. Plan monitoring around overlapping oral-therapy responsibilities, including anemia and oxygenation for belzutifan and blood pressure for lenvatinib.

PRIMARY RECORDS

Sources